Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 814 results for "bristol myers squibb"

Intraday Movers  Bristol-Myers Squibb, (NYSE:BMY), Centurylink, (NYSE:CTL)
News Is Money

Bristol-Myers Squibb's 3Q16 Earnings: What's Expected

With rising sales from products like Eliquis, Opdivo, and Hepatitis C franchise drugs, Bristol-Myers Squibb is expected to report growth of ~17% Yahoo! Finance, 16 hours ago

277 images for bristol myers squibb

American Banking News, 1 day ago
American Banking News, 1 day ago
Ticker Report, 2 days ago
World Pharma News, 1 week ago
Minyanville, 1 day ago
Live Trading News, 2 weeks ago, 2 weeks ago
Irish Times, 2 weeks ago
PharmaVOICE, 4 weeks ago
World Pharma News, 4 weeks ago

BRIEF-Bristol-Myers presents new results for opdivo (nivolumab)

n"Oct 25 Bristol-Myers Squibb Co : * New results presented for opdivo (nivolumab) demonstrate encouraging response rate in an expanded population of heavily pre-treated classical hodgkin lymphoma patients * Safety profile of opdivo consistent with ...
 Reuters UK19 hours ago BRISTOL MYERS SQUIBB : New Results Presented for Opdivo (nivolumab) Demonstrate Encouraging Response Rate in an Expanded Population of Heavily Pre-Treated Classical Hodgkin Lymphoma Patients  4 Traders20 hours ago Bristol-Myers Squibb's Ride Raises Over $1 Million For Cancer Research  BioSpace1 day ago Bristol-Myers Squibb Release: FDA Accepts For Priority Review The Supplemental Biologics License Application For Opdivo (Nivolumab) In Previously Treated Patients With Advanced Form Of Bladder Cancer  BioSpace1 day ago
Boston Globe

Devens rezoning clears final hurdle as MassDevelopment hunts for new biotech tenants

As they continue their hunt for the next Bristol-Myers Squibb, state officials have a new weapon to add to their arsenal. Town meeting voters in Harvard, Ayer, and Shirley approved a zoning change on Monday for nearly 33 acres in the sprawling ...
 Boston Globe13 hours ago

FDA accepts for priority review Bristol-Myers' sBLA for Opdivo for urothelial carcinoma use

The US Food and Drug Administration (FDA) has accepted for priority review Bristol-Myers Squibb's supplemental biologics license application (sBLA) for Opdivo (nivolumab) in previously treated patients With advanced form of bladder cancer. The ...
 Pharmaceutical Business Review17 hours ago FDA to Review Opdivo for Urothelial Carcinoma Use  Renal & Urology News1 day ago BRIEF-Bristol-Myers Squibb says U.S. FDA accepts for priority review the sBLA for Opdivo  Reuters UK4 days ago FDA Accepts for Priority Review the sBLA for Opdivo in Previously Treated Patients with Advanced Form of Bladder Cancer  American Pharmaceutical Review4 days ago

Bristol-Myers's (BMY) Opdivo Under Priority Review by FDA

Bristol-Myers Squibb Company BMY announced that its supplemental biologics license application (sBLA) for immuno-oncology drug Opdivo has been accepted for priority review by the FDA. The company is looking to expand Opdivo's label to include the ...
 Yahoo! Finance1 day ago

FDA accepts another Opdivo indication for priority review

The FDA has accepted a supplemental Biologics License Application (sBLA) for Bristol-Myers Squibb's Opdivo for treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) that has progressed on or after platinum-containing ...
 Pharmafile1 day ago FDA to review Bristol-Myers' marketing application for Opdivo for treatment-resistant bladder cancer; action date March 2  Seeking Alpha4 days ago

NICE U-turn brings breakthrough immunotherapy to kidney cancer patients in UK 21 Oct 2016

Bristol-Myers Squibb has announced that its breakthrough medicine Opdivo® (nivolumab) will be available from today (21 October) to NHS patients in England and Wales who have the most common form of kidney cancer . 1,2 In a reversal of its draft ...
 Medical News Today4 days ago Bristol Opdivo discount in kidney cancer changes minds at NICE  FiercePharma4 days ago NICE recommends breakthrough drug nivolumab for advanced renal cell cancer  European Pharmaceutical Review4 days ago NICE does U-turn, backs Opdivo in kidney cancer  pharmaphorum4 days ago
Motley Fool

3 Reasons Bristol-Myers Is a Buy

Image source: Bristol-Myers Squibb. Fresh off a data release announcement providing full details of Opdivo's failure in its Phase 3 CheckMate-026 study, Bristol-Myers Squibb ( NYSE:BMY ) shares dipped another 10%, bringing shares off a whopping ...
 Motley Fool6 days ago
Motley Fool

Pfizer and Bristol-Myers Squibb Could Face a Big Threat from Small Biotech Exelixis

Image source: . Only 12% of patients with advanced kidney cancer survive five years or more. Exelixis ( NASDAQ:EXEL ) hopes to increase that number, and based on its latest clinical trial results, the small biotech appears to be on the right ...
 Motley Fool1 week ago Comeback Kid Exelixis Could Pose a Huge Threat to Biotech Giants Bristol-Myers Squibb and Pfizer  BioSpace1 week ago

Bristol-Myers Wins CHMP Nod for Opdivo Label Expansion

Bristol-Myers Squibb Company BMY announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Opdivo for adults with relapsed or refractory classical Hodgkin lymphoma (cHL) ...
 Yahoo! Finance1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - bristol myers squibb
Get updated on latest news & your favorite topics right in your inbox!
More     Less